March 29, 2023
Regulatory reform to decriminalise the use of psilocybin is taking place in a dozen states across the US, and is
March 22, 2023
At the end of last year, Beckley Psytech announced the acquisition of life science company Eleusis. The procurement was largely
March 15, 2023
A clinical trial at the University of Wisconsin–Madison is studying psilocybin therapy in the treatment of methamphetamine and opioid use
February 22, 2023
MAPS recently announced positive results from its second Phase III trial with MDMA-assisted therapy in the treatment of PTSD, with
February 15, 2023
The UK is home to one of the largest gambling markets in the world, generating £14 billion in profit in
February 8, 2023
From 1 July, psychiatrists in Australia will be able to prescribe MDMA for PTSD and psilocybin for treatment-resistant depression. The
January 30, 2023
Tryp Therapeutics recently announced interim results from its Phase II trial with psilocybin in the treatment of binge eating disorder,
January 25, 2023
2023 is expected to be a pivotal year for psychedelic-assisted therapy, with multiple compounds entering the final stages of drug
January 18, 2023
Awakn Life Sciences announced that its Phase III clinical trial with ketamine-assisted therapy for the treatment of alcohol-use disorder would
January 10, 2023
On Friday, atai Life Sciences shared results from its Phase IIa trial with PCN-101, R-ketamine, for treatment-resistant depression. Disappointingly, the
January 4, 2023
The Psychedelics Newsletter is the sector’s best-read investment focused newsletter, with over 25,000 subscribers. Featuring in-depth market analysis and interviews
December 28, 2022
In the final quarter of 2022, Beckley Psytech shared updates on its drug development pipeline and reported the acquisition of
